Publications by authors named "P Ciraci"
Background: Despite a reduction of both incidence and mortality from CRC, recent studies have shown an increase in the incidence of early-onset CRC (EO-CRC). Data on this setting are limited. The aim of our study was to evaluate the clinical and molecular profiles of metastatic EO-CRC patients in order to identify differences compared to a late-onset CRC (LO-CRC) control group.
View Article and Find Full Text PDFOver the past few years, several novel systemic treatments have emerged for patients with treatment-refractory metastatic colorectal cancer, thus making selection of the most effective later-line therapy a challenge for medical oncologists. Over the past decade, regorafenib and trifluridine-tipiracil were the only available drugs and often provided limited clinical benefit compared to best supportive care. Results from subsequent practice-changing trials opened several novel therapeutic avenues, both for unselected patients (such as trifluridine-tipiracil plus bevacizumab or fruquintinib) and for subgroups defined by the presence of actionable alterations in their tumours (such as HER2-targeted therapies or KRAS inhibitors) or with no acquired mechanisms of resistance to the previously received targeted agents in circulating tumour DNA (such as retreatment with anti-EGFR antibodies).
View Article and Find Full Text PDFPurpose: KRASG12D mutation (mut) occurs in about 10%-12% of metastatic colorectal cancer (mCRC). Recently, novel KRASG12D inhibitors have been developed and are currently under investigation in phase I/II clinical trials in solid tumors including mCRC. We aimed at performing a comprehensive characterization of clinical, molecular, immunologic, and prognostic features of KRASG12D-mutated mCRC to inform the design and the interpretation of future trials.
View Article and Find Full Text PDFArticle Synopsis
- The PRODIGE-23 study indicates that FOLFIRINOX is more effective than neoadjuvant chemoradiotherapy alone in improving disease-free and overall survival for locally advanced rectal cancer.
- This research aims to evaluate survival rates, rates of pathological complete response, and safety of triplet versus doublet induction chemotherapy before further treatment.
- A systematic review of clinical trials was conducted to analyze data, focusing on comparison outcomes like disease-free survival and overall survival rates between different chemotherapy induction methods.
Background: Targeted therapy (TT) with encorafenib and cetuximab is the current standard for patients with BRAF-mutated metastatic colorectal cancer (mCRC) who received one or more prior systemic treatments. However, the median progression-free survival (mPFS) is ∼4 months, and little is known about the possibility of administering subsequent therapies, their efficacy, and clinicopathological determinants of outcome.
Methods: A real-world dataset including patients with BRAF-mutated mCRC treated with TT at 21 Italian centers was retrospectively interrogated.